High-dose-rate brachytherapy for airway malignancy a single institution experience

PURPOSE: To evaluate clinical outcomes of endobronchial malignancy treated using high-doserate endobronchial brachytherapy (HDREB).METHODS AND MATERIALS: A retrospective chart review was conducted for all patients treated with HDREB for malignant airway disease between 2010 and 2019 at a single institution. Most patients had a prescription of 14 Gy in two fractions given a week apart. The Wilcoxon signed rank test and paired samples t test were used to compare changes in mMRC dyspnea scale prior to and after brachytherapy at first followup appointment. Toxicity data were collected for dyspnea, hemoptysis, dysphagia, and cough.RESULTS: A total of 58 patients were identified. Most (84.5%) had primary lung cancer with advanced cancers, stage III or IV (86%). Eight were treated while admitted in the ICU. Previous external beam radiotherapy (EBRT) was received by 52%. An improvement in dyspnea was seen in 72%, with an mMRC dyspnoea scale score improvement of 1.13 points ( p < 0.001). Most (22, 88%) had an improvement in hemoptysis and 18 out of 37 (48.6%) had an improvement in cough. Grade four to five events occurred in 8 (13%) at the median time of 2.5 months from brachytherapy. Twenty-two patients (38%) had complete obstruction of the airway treated. Median progression free survival was 6.5 months and median survival was 10 months.CONCLUSIONS: We report a significant symptomatic benefit among patients receiving brachytherapy with endobronchial malignancy, with rates of treatment related toxicities similar to prior studies. Our study identified new subgroups of patients, ICU patients & those with complete obstruction, who benefited from HDREB. & COPY; 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Automated summary

The purpose of this study was to evaluate the clinical outcomes of endobronchial malignancy treated with high-doserate endobronchial brachytherapy (HDREB). A retrospective chart review showed that most patients experienced improvement in dyspnea, cough, and hemoptysis after treatment, with minimal treatment-related toxicities.